Metraipolis › archive › dc_4b8524f8a070
Characterization of ocular adverse events associated with crizotinib: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase — Europe PMC PMID:41458610
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41458610
- DOI
- 10.3389/fonc.2025.1735200
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T17:05:47.403Z
- SHA-256 of the archived text
6a84d78ad8efbc073d8197b17a7d57c15df0a3d1665481d36a8ced5594d1f47f- Stable URL of this page
https://metraipolis.com/documento/dc_4b8524f8a070
How to cite
Characterization of ocular adverse events associated with crizotinib: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase — Europe PMC PMID:41458610 — Europe PMC (en), https://europepmc.org/article/MED/41458610 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4b8524f8a070 (Metraipolis archive dc_4b8524f8a070, sha256 6a84d78ad8efbc073d8197b17a7d57c15df0a3d1665481d36a8ced5594d1f47f)
BibTeX
@misc{dc4b8524f8a070,
title = {Characterization of ocular adverse events associated with crizotinib: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase — Europe PMC PMID:41458610},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41458610},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4b8524f8a070; sha256 6a84d78ad8efbc073d8197b17a7d57c15df0a3d1665481d36a8ced5594d1f47f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41458610. Agents can read the archived copy with the MCP tool read_document.